Xeris Pharmaceuticals Closes US$1.5 Million Series A Financing with Central Texas Angel Network

Published: Dec 12, 2011

AUSTIN, Texas--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a biopharmaceutical company developing the G-Pen™, a glucagon rescue pen for emergency treatment of severe hypoglycemia, has completed a Series A preferred stock financing for approximately $1.5 million. The financing was led by the Central Texas Angel Network (CTAN), with significant participation of life science investors including family offices from California and Tennessee.

Back to news